Pablo Lapuerta

Internal Medicine

5 Seminole Rd
Skillman, NJ 08558

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of Adiponectin Agonist (PEG)-BHD1028 in People With Insulin Resistance.

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of Adiponectin Agonist (PEG)-BHD1028 in People With Insulin Resistance.

Journal: Clinical and translational science

Published: December 17, 2025

Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.

Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 22, 2025

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.

Journal: Clinical pharmacology and therapeutics

Published: October 30, 2023

Telotristat ethyl reverses myxomatous changes in mice mitral valves.

Telotristat ethyl reverses myxomatous changes in mice mitral valves.

Journal: Frontiers in cardiovascular medicine

Published: May 16, 2022

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.

Journal: Diabetes, obesity & metabolism

Published: May 17, 2021

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.

Journal: The New England journal of medicine

Published: November 17, 2020

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Journal: The New England journal of medicine

Published: November 17, 2020

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.

Journal: Neuroendocrinology

Published: October 07, 2020

Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome.

Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome.

Journal: Cancer management and research

Published: August 19, 2020

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.

Journal: Diabetes technology & therapeutics

Published: July 30, 2020

Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study.

Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study.

Journal: Cancer management and research

Published: May 06, 2020

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.

Journal: Diabetes care

Published: April 23, 2020

Showing 1-12 of 49

Last Updated: 09/26/2026